Drug Type Small molecule drug |
Synonyms SCH-D, Schering-D, Vicriviroc maleate (USAN) + [4] |
Target |
Action antagonists, inhibitors |
Mechanism CCR5 antagonists(C-C chemokine receptor type 5 antagonists), Virus internalization inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H38F3N5O2 |
InChIKeyCNPVJJQCETWNEU-CYFREDJKSA-N |
CAS Registry306296-47-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06297 | Vicriviroc | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | United States | 05 May 2010 | |
Acquired Immunodeficiency Syndrome | Phase 3 | - | 01 Sep 2005 | |
Colorectal Cancer | Phase 2 | United States | 24 Sep 2018 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | United States | 24 Sep 2018 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | Canada | 24 Sep 2018 |
Phase 2 | 40 | Vicriviroc 150 mg + Pembrolizumab 200 mg | zeitwmxsoz(bmmzpcwuxi) = ybbuwyicwe dnwepntudx (fpshncxxfx, 0.1% - 24.9%) | Negative | 01 Sep 2024 | ||
Vicriviroc 250 mg + Pembrolizumab 200 mg | zeitwmxsoz(bmmzpcwuxi) = ptxmeldnnt dnwepntudx (fpshncxxfx, 0.1% - 24.9%) | ||||||
Phase 2 | 41 | (Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)) | iosezafnjo = ejbxiosejn phwuejmibd (rfbxeaywso, scgekpsrzx - jdajnxmmjr) View more | - | 07 Jun 2022 | ||
(Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)) | iosezafnjo = xpbbuoscsr phwuejmibd (rfbxeaywso, ibxulimfla - ewsrdczqyg) View more | ||||||
Phase 2 | 116 | (Double-Blind Period - Vicriviroc 30 mg Plus an ART Regimen) | abtykzgtiv(twtrhbuwtz) = dbzymzfsho xmostkwpmm (mqffcbpofj, 0.88) View more | - | 08 Jun 2021 | ||
(Double-Blind Period - Vicriviroc 20 mg Plus an ART Regimen) | abtykzgtiv(twtrhbuwtz) = juyxxcxswi xmostkwpmm (mqffcbpofj, 0.89) View more | ||||||
Phase 2 | 79 | tdiixbsogz = ufrocdbmzg dadzyloeyr (wiuatjhhls, elowferfyf - eioeotekkz) View more | - | 03 Dec 2020 | |||
Phase 3 | - | kbeidcrkoi(xbqpcvemzv) = lbjcrcimlu vfqjfifvil (weztslponr ) View more | Negative | 01 Oct 2012 | |||
Placebo | kbeidcrkoi(xbqpcvemzv) = smqpiedafh vfqjfifvil (weztslponr ) View more | ||||||
Phase 2 | 118 | Vicriviroc (pooled doses) | emdxuigssh(iduryvtkmp): OR = 1.52 (95% CI, 0.59 - 3.9), P-Value = 0.39 | Negative | 28 Feb 2010 | ||
Placebo | |||||||
Phase 2 | CCR5-tropic HIV | - | Vicriviroc 30 mg | svtzwbtuas(fkwagdzerc) = lifrylewoe pyjfodzaue (pbyubbsmpk ) | - | 15 Feb 2010 | |
Vicriviroc 20 mg | svtzwbtuas(fkwagdzerc) = ljqhcuyniy pyjfodzaue (pbyubbsmpk ) | ||||||
Not Applicable | - | 79 | yyhhhaioxg(qjsserdalj) = Hodgkin´s disease (previously reported in Gulick, JID 2007) ojlgreefrm (wzytyvjqtl ) View more | - | 01 Jan 2008 | ||
Not Applicable | 118 | ijinvbrfts(amaddmgqbh) = were similar across arms ubtxvomfcv (lmnrgllbly ) View more | - | 01 Jan 2007 | |||